and vascular progenitor cells for metabolic and ischemic diseases. Its approach involves the use of pluripotent stem cells to generate differentiated cell types with potential clinical uses. AgeX also investigates methods to reduce immune rejection through gene-editing and cell engineering. It conducts preclinical and strategic development in collaboration with research institutions and partners. AgeX operates within the biotech sector with an emphasis on therapeutic innovation and regulatory compliance.